|Articles|June 1, 2004
Multiple studies support flexible approach to treating actinic keratoses with imiquimod
In early March, the FDA granted marketing approval for use of imiquimod cream in the treatment of nonhyperkeratotic, nonhypertrophic AKs on the scalp or face in immunocompetent individuals.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5














